GlobeNewswire by notified

Interim report 2022/23 - 15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter

Share

ANNOUNCEMENT NO. 234
9 February 2023
Interim report for the first half of 2022/23


15% revenue growth and DKK 145 million operating profit (+25%) for the first half following a challenging second quarter

Steen Søndergaard, CEO: “Following a very satisfactory 2021/22 with historically high revenue and operating profit growth rates, revenue for the first half of 2022/23 unfortunately disappointed, despite 15% growth. Second quarter sales of instruments, particularly in the North American market, were challenged by a generally more subdued investment sentiment in our primary business segment, cell-based therapy. Our order intake was mainly impacted by weakened demand from capital-sensitive development companies. On the other hand, we saw continued satisfactory growth in sales of consumables and services.

Despite the unfavourable market conditions, our earnings continued to grow. While our market is currently affected by the prevailing macroeconomic environment, we have a strong underlying business and a highly competitive product portfolio, and I am confident that the launch of our new XcytoMatic instruments will further strengthen our market position in the coming years.”


Sales and operating results

  • First half revenue amounted to DKK 240.6 million, a 15% year-on-year increase. Revenue growth was evenly distributed across ChemoMetec’s regions.
  • Sales of instruments were down 5%, mainly due to a decline in sales to capital-sensitive customers.
  • Revenue growth was driven by higher sales of consumables and services, up 33% and 53%, respectively. Sales of consumables and services each accounted for 37% and 17% of total revenue, compared with 32% and 13% in the year-earlier period.
  • Revenue in ChemoMetec’s core business area, LCB (Life science research, Cell-based therapy and Bioprocessing), increased 15% in the first half and accounted for 93% of total revenue.
  • EBITDA increased 25% to DKK 145.2 million, and the EBITDA margin was 60%, compared with 55% in the year-earlier period.
  • Revenue and EBITDA both benefited from a strengthened USD, which was 15% up on the year-earlier period, on average. At constant exchange rates, revenue growth was approximately 6% and EBITDA growth approximately 12%.
  • ChemoMetec sold and delivered the first prototype of the new XcytoMatic 40 (XM40) instrument towards the end of October 2022. Production of the XM40 is still expected to be established during the first quarter of 2023.
  • Based on the performance in the first half, and due to continued uncertainty about the global economic outlook and general market conditions, our current guidance for the 2022/23 financial year is a revenue of DKK 430-460 million, against the previous guidance of DKK 485-505 million. The guidance for EBITDA for the financial year 2022/23 is maintained at DKK 245-260 million.


The interim report for the first half of 2022/23 is attached to this announcement.



Additional information

Steen Søndergaard, CEO
Telephone: +45 4813 1020        

Niels Høy Nielsen, CFO
Telephone: +45 2551 8724



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go towww.chemometec.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Storaktionærmeddelelse25.3.2023 14:30:37 CET | pressemeddelelse

Årets meddelelse nr. 20 Dato: 25. marts 2023 Storaktionærmeddelelse Det skal herved meddeles, at Pharma Equity Group A/S har modtaget meddelelse om at NK Invest ApS ejerandel, både direkte og indirekte via dennes ejerskab af Selskabet af 25. marts DK ApS og Selskabet af 25. marts II ApS, efter kapitalforhøjelse offentliggjort under selskabsmeddelelse nr. 16 af 24. marts 2023, udgør mindre end 5 % af den udstedte aktiekapital i Pharma Equity Group A/S. Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mail: peter.ole.jensen@pharmaequitygroup.com. Med venlig hilsen Pharma Equity Group A/S På bestyrelsens vegne

FCB Tops 2023 WARC Rankings for Creative Effectiveness24.3.2023 21:41:59 CET | Press release

FCB awarded #1 Creative Agency & #1 Campaign for Effectiveness in WARC Effective 100 NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- FCB was a top performer in the 2023 WARC Rankings, earning recognition as the #1 Creative Agency for Effectiveness in the WARC Effective 100, among other distinctions. Numerous FCB campaigns were honored as well, including Michelob ULTRA’s “Contract for Change,” which ranked as the #1 Campaign for Effectiveness. “Creative is the business and the business is creative. To separate the two does a disservice to the industry. We will continue to partner with our clients to create work that is both effective in the moment and impactful long term. FCB is honored that this Timely and Timeless approach to work is being recognized by WARC,” said Susan Credle, FCB Global Chair & Global CCO. In the Effective 100, FCB New York was named the #1 Creative Agency for Effectiveness, joined by two additional FCB agencies, with FCB Chicago ranking #4 and FCB Toronto ranking #7,

Ordinary and Extraordinary General Meeting of April 12, 202324.3.2023 21:30:00 CET | Press release

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Meeting”) on April 12, 2023, at 10:00 a.m. CET at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 8, 2023 (No. 2300429). The meeting notice (avis de convocation) was published in the French “Bulletin des AnnoncesLégalesObligatoires (BALO)” dated March 24, 2023 (No. 2300600) and in the legal newspaper Affiches pari

TGS: Approval of 2022 Financial Result24.3.2023 20:03:58 CET | Press release

Oslo, Norway (24 March 2023) – The Board of Directors of TGS ASA has today approved the financial statements for 2022. The financial statements were prepared in accordance with IFRS. Please see the attachment for a summary of changes from the preliminary annual accounts announced on 9 February 2023. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. For more information, visit TGS.com (http://www.tgs.com) or contact: Sven Børre Larsen CFO Tel: +47 90 94 36 73 E-mail: investor@tgs.com Attachment TGS Annual Accounts 2022 update

Nokia Corporation: Repurchase of own shares on 24.03.202324.3.2023 20:00:00 CET | Press release

Nokia Corporation Stock Exchange Release 24 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 24.03.2023 Espoo, Finland – On 24 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL306,0764.31CEUX7,3924.31AQEU2,6084.31TQEX6,3244.32Total322,4004.31 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 January 2023 and